Thelansis

 Actinic keratosis (AK) are common cutaneous lesion associated with chronic exposure to ultraviolet (UV) radiation. AK presents scaly, erythematous papules or plaque and is considered the earliest clinically recognizable manifestation of squamous cell carcinoma (SCC). Actinic keratosis prevalence is estimated to be between 2.45% to 2.7% among patients of all ages. Prevalence is as lowest as 0.1% in the age group of 30-39 years and estimated highest at ~15.5% among the >80 years age people. Thelansis’s “Actinic Keratosis (AK) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Actinic Keratosis (AK) treatment modalities options for eight major markets (USA, Germany, France, It...